Production (Stage)
Axsome Therapeutics, Inc.
AXSM
$103.98
-$1.09-1.04%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 13.08% | 24.06% | -3.86% | -18.13% | -509.35% |
| Total Depreciation and Amortization | 16.49% | 19.14% | 18.24% | 18.00% | 10.17% |
| Total Amortization of Deferred Charges | 7.75% | 55.95% | 7.18% | -29.48% | 5.99% |
| Total Other Non-Cash Items | 21.51% | -47.14% | 150.68% | 5.65% | 50.63% |
| Change in Net Operating Assets | -49.10% | 273.69% | 156.09% | 272.97% | 29.29% |
| Cash from Operations | 18.88% | 13.70% | 65.21% | 45.60% | -818.52% |
| Capital Expenditure | -244.90% | -328.57% | 75.74% | 60.90% | -38.03% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -244.90% | -328.57% | 75.74% | 60.90% | -38.03% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -146.01% | -- | -- | -- | -- |
| Issuance of Common Stock | 1,366.81% | 1,434.24% | -12.28% | -92.22% | 546.25% |
| Repurchase of Common Stock | -167.99% | -90.36% | -33.24% | -298.80% | -86.62% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -40.43% | -183.74% | 49.29% | 86.06% | 35.47% |
| Cash from Financing | 2,565.88% | 712,300.00% | -8.89% | -94.16% | -102.30% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 73.62% | 60.53% | 156.86% | -108.28% | -219.88% |